The National Cancer Institute approved the following clinical research studies last month.
In an industry that set its sights on reshaping cancer detection, GRAIL Inc. had the appearance of a pioneer.
NCI has launched a second-generation precision medicine clinical trial called Myeloid Malignancies Molecular Analysis for Therapy Choice, or myeloMATCH, a trial focused on acute myeloid leukemia and myelodysplastic syndromes.
The University of Hawai‘i Cancer Center has received a full five-year designation from NCI.
ECOG-ACRIN Cancer Research Group and Caris Life Sciences announced a multi-year research collaboration wherein Caris is pairing its genomic, transcriptomic, and proteomic profiling, advanced artificial intelligence and machine learning algorithms with ECOG-ACRIN’s research capabilities.
Modifi Biosciences Inc., a Yale University spinout company formed in 2021 that develops direct DNA-modification-enabled cancer therapeutics, has been acquired by Merck.
Marshall Posner, physician-scientist and head-and-neck oncologist, joined TGH Cancer Institute | Cancer Center of South Florida, effective Oct. 1.
Greg Sawyer, chair of the bioengineering department at Moffitt Cancer Center, has been awarded the 2023 Tribology Gold Medal by the International Tribology Council. This prestigious award is the highest honor in the field and recognizes individuals who have made extraordinary lifetime contributions to the study of friction, wear, and lubrication.
Thomas Bradley has been appointed director of hematology and oncology at Staten Island University Hospital’s Florina Cancer Center to spearhead the division’s clinical, educational, and research initiatives.
Kate Hitchcock, a UF Health radiation oncologist and an associate professor in the Department of Radiation Oncology in the UF College of Medicine, has been named associate director for access and opportunities at the UF Health Cancer Center. In this role, she will use her experience in leading clinical trials and broad range of healthcare experience to help the center train the next generation of cancer researchers, preparing them to lead advancements in the field.
